{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T19:24:20Z","timestamp":1784921060941,"version":"3.55.0"},"reference-count":24,"publisher":"Termedia Sp. z.o.o.","issue":"1","license":[{"start":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T00:00:00Z","timestamp":1586131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"},{"start":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T00:00:00Z","timestamp":1586131200000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"},{"start":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T00:00:00Z","timestamp":1586131200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cent Eur J Immunol"],"abstract":"<jats:p>Systemic lupus erythematosus (SLE) is a\u00a0disease of unclear causes, which leads to major immunological disorders. It is characterized by an abnormal immune system activity resulting in the production of autoantibodies. In patients, antibodies targeting normal nuclear components, double-stranded DNA (dsDNA), and phospholipids (cardiolipin) can be detected. The inflammatory process occurs in various tissues and organs, damaging their functions and structure. Disease\u2019s course includes stages of acute symptoms and remissions, and there is no known cure. Pathogenesis and biochemical pathways accompanying systemic lupus erythematosus are widely studied, as existing medication can only bring temporary relief to patients. The recent findings suggest that occurrence of SLE depends on interactions between genetic background of the disease and environmental risk factors such as exposure to tobacco smoke, chemical factors, and hormonal therapy. In the addition, chronic inflammation accompanying SLE disturbs oxidative\/antioxidative balance. These processes are linked to intensified advanced glycation end products (AGEs) formation, thus level of AGEs themselves and their receptors (RAGE, sRAGE) are gaining researches attention.<\/jats:p>","DOI":"10.5114\/ceji.2018.77875","type":"journal-article","created":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T06:13:42Z","timestamp":1590128022000},"page":"93-98","source":"Crossref","is-referenced-by-count":8,"title":["Systemic lupus erythematosus and glycation proces"],"prefix":"10.5114","volume":"45","author":[{"given":"Agnieszka","family":"Nowak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brygida","family":"Przywara-Chowaniec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystyna","family":"Tyrpie\u0144-Golder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Nowalany-Kozielska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3061","published-online":{"date-parts":[[2020,4,6]]},"reference":[{"key":"ref-1546872","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0140-6736(07)60279-7","article-title":"Systemic lupus erythematosus","volume":"369","author":"D\u2019Cruz PD","year":"2007","unstructured":"D\u2019Cruz PD, Khamashta MA, Hughes GRV (2007): Systemic lupus erythematosus. The Lancet 369: 587-596.","journal-title":"The Lancet"},{"key":"ref-1546873","author":"Szczeklik A","year":"2011","unstructured":"Szczeklik A, Gajewski P (2011): Choroby wewn\u0119trzne. Medycyna Praktyczna, Krak\u00f3w."},{"key":"ref-1546874","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1546-0096-12-50","article-title":"The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus","volume":"12","author":"Bobek D","year":"2014","unstructured":"Bobek D, Gr\u010devi\u0107 D, Kova\u010di\u0107 N, et al. (2014): The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus. Pediatr Rheumatol Online J 12: 50","journal-title":"Pediatr Rheumatol Online J"},{"key":"ref-1546875","article-title":"1997 update of the 1982 American College of Rheumatology revised criteria for classification of systemic lupus erythematosus","unstructured":"1997 update of the 1982 American College of Rheumatology revised criteria for classification of systemic lupus erythematosus. https:\/\/www.rheumatology.org\/Portals\/0\/Files\/1997%20Update%20of%201982%20Revised.pdf. Updated February 2015."},{"key":"ref-1546876","first-page":"447","article-title":"The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus","volume":"86","author":"Hay EM","year":"1993","unstructured":"Hay EM, Bacon PA, Gordon C, et al. (1993): The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 86: 447-458.","journal-title":"Q J Med"},{"key":"ref-1546877","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/art.1780350606","article-title":"Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE","volume":"35","author":"Bombardier C","year":"1992","unstructured":"Bombardier C, Gladman DD, Urowitz MB, et al. (1992): Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35: 630-640.","journal-title":"Arthritis Rheum"},{"key":"ref-1546878","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/rheumatology\/ken302","article-title":"Skin autofluorescence is increased in systemic lupus erythematosus but is not reflected by elevated plasma levels of advanced glycation endproducts","volume":"47","author":"Nienhuis HL","year":"2008","unstructured":"Nienhuis HL, de Leeuw K, Bijzet J, et al. (2008): Skin autofluorescence is increased in systemic lupus erythematosus but is not reflected by elevated plasma levels of advanced glycation endproducts. Rheumatology (Oxford) 47: 1554-1558.","journal-title":"Rheumatology (Oxford)"},{"key":"ref-1546879","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/rheumatology\/kem215","article-title":"Accumulation of advanced glycation endproducts in patients with systemic lupus erythematosus","volume":"46","author":"de Leeuw K","year":"2007","unstructured":"de Leeuw K, Graaff R, de Vries R, et al. (2007): Accumulation of advanced glycation endproducts in patients with systemic lupus erythematosus. Rheumatology (Oxford) 46: 1551-1556.","journal-title":"Rheumatology (Oxford)"},{"key":"ref-1546880","first-page":"497","article-title":"Environmental exposures and the development of systemic lupus erythematosus","volume":"28","author":"Barbhaiya M","year":"2016","unstructured":"Barbhaiya M, Costenbader KH (2016): Environmental exposures and the development of systemic lupus erythematosus. CurrOpinRheumatol 28: 497-505.","journal-title":"CurrOpinRheumatol"},{"key":"ref-1546881","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/S0140-6736(14)60128-8","article-title":"Systemic lupus erythematosus","volume":"384","author":"Lisnevskaia L","year":"2014","unstructured":"Lisnevskaia L, Murphy G, Isenberg D (2014): Systemic lupus erythematosus. Lancet 384: 1878-1888.","journal-title":"Lancet"},{"key":"ref-1546882","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1136\/ard.2005.039438","article-title":"Association of smoking with dsDNA autoantibody production in systemic lupus erythematosus","volume":"65","author":"Freemer MM","year":"2006","unstructured":"Freemer MM, KingJr TE, Criswell LA (2006): Association of smoking with dsDNA autoantibody production in systemic lupus erythematosus. Ann Rheum Dis 65: 581-584.","journal-title":"Ann Rheum Dis"},{"key":"ref-1546883","doi-asserted-by":"crossref","first-page":"101","DOI":"10.5606\/tjr.2013.2845","article-title":"A soluble receptor for advanced glycation end product levels in patients with systemic lupus erythematosus","volume":"208","author":"Bayoumy N","year":"2013","unstructured":"Bayoumy N, El-Shabrawi M, Nada H (2013): A soluble receptor for advanced glycation end product levels in patients with systemic lupus erythematosus. Arch Rheumatol 208: 101-108.","journal-title":"Arch Rheumatol"},{"key":"ref-1546884","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.autrev.2008.04.019","article-title":"Autoimmunity and oxidatively modified autoantigens","volume":"7","author":"Kurien BT","year":"2008","unstructured":"Kurien BT, Scofield H (2008): Autoimmunity and oxidatively modified autoantigens. Autoimmun Rev 7: 567-573.","journal-title":"Autoimmun Rev"},{"key":"ref-1546885","first-page":"684","article-title":"Serum oxidant\/antioxidant status of patients with systemic lupus erythematosus","volume":"40","author":"Taysi S","year":"2002","unstructured":"Taysi S, Gul M, Sari RA, et al. (2002): Serum oxidant\/antioxidant status of patients with systemic lupus erythematosus. Clin Chem Lab Med 40: 684-688.","journal-title":"Clin Chem Lab Med"},{"key":"ref-1546886","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12891-015-0569-3","article-title":"The potential role of advanced glycation end products (AGEs) and soluble receptors for AGEs (sRAGE) in the pathogenesis of adult-onset still\u2019s disease","volume":"16","author":"Chen DY","year":"2015","unstructured":"Chen DY, Chen YM, Lin CC, et al. (2015): The potential role of advanced glycation end products (AGEs) and soluble receptors for AGEs (sRAGE) in the pathogenesis of adult-onset still\u2019s disease. BMC Musculoskelet Disord 16: 111","journal-title":"BMC Musculoskelet Disord"},{"key":"ref-1546887","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1471-2474-11-83","article-title":"Increased concentration of two different advanced glycation end-products detected by enzyme immunoassays with new monoclonal antibodies in sera of patients with rheumatoid arthritis","volume":"11","author":"Vyt\u00e1\u0161ek R","year":"2010","unstructured":"Vyt\u00e1\u0161ek R, \u0160edov\u00e1 L, Vil\u00edm V (2010): Increased concentration of two different advanced glycation end-products detected by enzyme immunoassays with new monoclonal antibodies in sera of patients with rheumatoid arthritis. BMC Musculoskelet Disord 11: 83","journal-title":"BMC Musculoskelet Disord"},{"key":"ref-1546888","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/clinchem\/44.2.250","article-title":"Increased concentrations of serum pentosidine in rheumatoid arthritis","volume":"44","author":"Rodr\u00edguez-Garc\u00eda J","year":"1998","unstructured":"Rodr\u00edguez-Garc\u00eda J, Requena JR, Rodr\u00edguez-Segade S (1998): Increased concentrations of serum pentosidine in rheumatoid arthritis. Clin Chem 44: 250-255.","journal-title":"Clin Chem"},{"key":"ref-1546889","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1172\/JCI200114002","article-title":"The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses","volume":"108","author":"Schmidt AM","year":"2001","unstructured":"Schmidt AM, Yan SD, Yan SF, Stern DM (2001): The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 108: 949-955.","journal-title":"J Clin Invest"},{"key":"ref-1546890","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1093\/rheumatology\/ket263","article-title":"Increased serum levels of S100A8\/A9 and S100A12 are associated with cardiovascular disease in patients with inactive systemic lupus erythematosus","volume":"52","author":"Tyd\u00e9n H","year":"2013","unstructured":"Tyd\u00e9n H, Lood C, Gullstrand B, et al. (2013): Increased serum levels of S100A8\/A9 and S100A12 are associated with cardiovascular disease in patients with inactive systemic lupus erythematosus. Rheumatology (Oxford) 52: 2048-2055.","journal-title":"Rheumatology (Oxford)"},{"key":"ref-1546891","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1365-3083.2012.02691.x","article-title":"The plasma level of soluble receptor for advanced glycation end products is decreased in patients with systemic lupus erythematosus","volume":"75","author":"Ma CY","year":"2012","unstructured":"Ma CY, Ma JL, Jiao YL, et al. (2012): The plasma level of soluble receptor for advanced glycation end products is decreased in patients with systemic lupus erythematosus. Scand J Immunol 75: 614-622.","journal-title":"Scand J Immunol"},{"key":"ref-1546892","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1084\/jem.20120201","article-title":"RAGE is a nucleic acid receptor that promotes inflammatory responses to DNA","volume":"210","author":"Sirois CM","year":"2013","unstructured":"Sirois CM, Jin T, Miller AL, et al. (2013): RAGE is a nucleic acid receptor that promotes inflammatory responses to DNA. J Exp Med 210: 2447-2463.","journal-title":"J Exp Med"},{"key":"ref-1546893","first-page":"151","article-title":"The plasma level of soluble receptor for advanced glycation end products in systemic lupus erythematosus patients and its relation to disease activity","volume":"52","author":"Abou-Raya AN","year":"2016","unstructured":"Abou-Raya AN, Nabi Kamel MA, Ghani Sayed EA, Hamid El-Sharkawy AA (2016): The plasma level of soluble receptor for advanced glycation end products in systemic lupus erythematosus patients and its relation to disease activity. AJM 52: 151-157.","journal-title":"AJM"},{"key":"ref-1546894","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/0961203314559631","article-title":"Members of the receptor for advanced glycation end products axis as potential therapeutic targets in patients with lupus nephritis","volume":"24","author":"Yu SL","year":"2015","unstructured":"Yu SL, Wong CK, Szeto CC, et al. (2015): Members of the receptor for advanced glycation end products axis as potential therapeutic targets in patients with lupus nephritis. Lupus 24: 675-686.","journal-title":"Lupus"},{"key":"ref-1546895","doi-asserted-by":"crossref","first-page":"e0178404","DOI":"10.1371\/journal.pone.0178404","article-title":"Plasma levels of high-mobility group box 1 and soluble receptor for advanced glycation end products in primary antiphospholipid antibody syndrome patients","volume":"12","author":"Tang KT","year":"2017","unstructured":"Tang KT, Hsieh TY, Chao YH, et al. (2017): Plasma levels of high-mobility group box 1 and soluble receptor for advanced glycation end products in primary antiphospholipid antibody syndrome patients. PLoS One 12: e0178404","journal-title":"PLoS One"}],"container-title":["Central European Journal of Immunology"],"original-title":[],"link":[{"URL":"https:\/\/ceji.termedia.pl\/pdf-85703-129806","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ceji.termedia.pl\/pdf-85703-129806","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T08:35:12Z","timestamp":1767947712000},"score":1,"resource":{"primary":{"URL":"https:\/\/ceji.termedia.pl\/Systemic-lupus-erythematosus-and-glycation-proces,85703,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,6]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"alternative-id":["85703"],"URL":"https:\/\/doi.org\/10.5114\/ceji.2018.77875","relation":{},"ISSN":["1426-3912","1644-4124"],"issn-type":[{"value":"1426-3912","type":"print"},{"value":"1644-4124","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,6]]}}}